News
Hosted on MSN6mon
Amgen downgraded at Truist on MariTide prospects for obesityAnalyst Robyn Karnauskas wrote that when phase 2 data on MariTide, a GLP-1 receptor and gastric inhibitory polypeptide receptor comes out, it will likely reflect prior data. And given the current ...
Hosted on MSN1mon
Zealand and Roche strike $5.3bn obesity treatment dealThe first planned combination will pair petrelintide with Roche’s glucagon-like peptide 1/gastric inhibitory polypeptide (GLP ... which is dominated by GLP-1 receptor agonists (GLP-1RAs) such ...
The candidate, UBT251, is a long-acting synthetic peptide triple agonist targeting the receptors for (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon, and is currently in early-stage ...
The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback